摘要
目的:观察芪味糖平胶囊干预治疗糖耐量受损(IGT)患者对糖尿病(DM)发病率的作用以及逆转为正常糖耐量(NGT)的作用。方法:以口服75 g葡萄糖耐量试验(OGTT)作为筛选条件,按1999年WHO诊断标准选取我院100例IGT患者,并对其进行2年前瞻性研究。将所有患者随机分为试验组与对照组,每组50例。入选患者不被干预其生活方式,只对其进行一般的IGT知识宣教。试验组给予口服芪味糖平胶囊治疗,每次3粒,每日2次;对照组给予口服芪味糖平胶囊模拟剂治疗,每次3粒,每日2次。疗程为24个月。结果:治疗2年后,试验组由IGT转为DM者为4.17%,对照组为25.53%;试验组由IGT转为NGT者为50.00%,对照组为17.02%;两组比较差异有统计学意义(P<0.01)。结论:芪味糖平胶囊有改善胰岛素抵抗和胰岛β细胞功能的作用,芪味糖平胶囊干预治疗IGT是预防IGT向2型DM发展的有效措施。
Objective：To evaluate the effects of Qiwei Tangping Capsule on conversion to DM or NGT in IGT patients.Methods：In this 2 years prospective study,100 patients with IGT were included.IGT was defined by 1999 WHO criteria in the method of utilizing 75 g oral glucose tolerance test（OGTT）.All patients were randomly divided into the treatment group（50 cases） and control groups（50 cases）.Their lifeway weren’t intervened,but only were given IGT knowledge education.The treatment group was given Qiwei Tangping Capsule at the dose of 3 Capsule（twice per day）,and the control group was given Placebo Capsule at the dose of 3 Capsule（twice per day）.The study lasted for 24 months.Results：The ratio of IGT which converted to DM was 4.17% in treatment group and 25.53% in control group,and the ratio of IGT which converted to NGT was 50.00% in treatment group and 17.02% in control group（P〈0.01）.Conclusion：Intervention treatment with Qiwei Tangping Capsule is one of the effective measures in preventing the conversion of IGT to DM.
出处
《中国医药导报》
CAS
2011年第10期101-103,共3页
China Medical Herald
基金
河北省科技攻关项目(项目名称:芪味糖平胶囊干预治疗糖耐量减低的临床及作用机理研究
项目编号:062761394)
